BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2449840)

  • 1. Regulation of the expression of class II genes of the human major histocompatibility complex in tumor cells.
    Gambari R; Barbieri R; Piva R; Tecce R; Fisher PB; Giacomini P; Natali PG
    Ann N Y Acad Sci; 1987; 511():292-307. PubMed ID: 2449840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter.
    Deffrennes V; Vedrenne J; Stolzenberg MC; Piskurich J; Barbieri G; Ting JP; Charron D; Alcaïde-Loridan C
    J Immunol; 2001 Jul; 167(1):98-106. PubMed ID: 11418637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of Fc receptor for IgE (CD23) and class II MHC antigen expression on Burkitt's lymphoma cell lines by human IL-4 and IFN-gamma.
    Rousset F; Malefijt RW; Slierendregt B; Aubry JP; Bonnefoy JY; Defrance T; Banchereau J; de Vries JE
    J Immunol; 1988 Apr; 140(8):2625-32. PubMed ID: 2965726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells.
    Nisticò P; Tecce R; Giacomini P; Cavallari A; D'Agnano I; Fisher PB; Natali PG
    Cancer Res; 1990 Dec; 50(23):7422-9. PubMed ID: 1701342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of major histocompatibility complex class II gene expression and demonstration of antigen-specific T cell response indicate a new phenotype in class II-deficient patients.
    Hauber I; Gulle H; Wolf HM; Maris M; Eggenbauer H; Eibl MM
    J Exp Med; 1995 Apr; 181(4):1411-23. PubMed ID: 7699327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines.
    Rodríguez T; Méndez R; Del Campo A; Aptsiauri N; Martín J; Orozco G; Pawelec G; Schadendorf D; Ruiz-Cabello F; Garrido F
    Immunogenetics; 2007 Feb; 59(2):123-33. PubMed ID: 17180681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization.
    Muczynski KA; Anderson SK; Pious D
    J Immunol; 1998 Apr; 160(7):3207-16. PubMed ID: 9531276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.
    Lu HT; Riley JL; Babcock GT; Huston M; Stark GR; Boss JM; Ransohoff RM
    J Exp Med; 1995 Nov; 182(5):1517-25. PubMed ID: 7595221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-induced expression of class II major histocompatibility antigens in the major histocompatibility complex (MHC) class II deficiency syndrome.
    Plaeger-Marshall S; Haas A; Clement LT; Giorgi JV; Chen IS; Quan SG; Gatti RA; Stiehm ER
    J Clin Immunol; 1988 Jul; 8(4):285-95. PubMed ID: 2457596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of the antigenic phenotype of human melanoma cells by recombinant interferons.
    Giacomini P; Gambari R; Barbieri R; Nisticò P; Tecce R; Pestka S; Gustafsson K; Natali PG; Fisher PB
    Anticancer Res; 1986; 6(5):877-84. PubMed ID: 2432832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of HLA class II antigens in osteosarcoma cells by interferons and tumor necrosis factor alpha.
    Scotlandi K; Baldini N; Campanacci M; Lollini PL; Picci P; Serra M
    Anticancer Res; 1992; 12(3):767-72. PubMed ID: 1622136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of class II MHC molecules on human endothelial cells. Effects of IFN and dexamethasone.
    Manyak CL; Tse H; Fischer P; Coker L; Sigal NH; Koo GC
    J Immunol; 1988 Jun; 140(11):3817-21. PubMed ID: 2453556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of class II expression in monocytic cells after HIV-1 infection.
    Rakoff-Nahoum S; Chen H; Kraus T; George I; Oei E; Tyorkin M; Salik E; Beuria P; Sperber K
    J Immunol; 2001 Aug; 167(4):2331-42. PubMed ID: 11490022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major histocompatibility class II HLA-DR alpha gene expression in thyrocytes: counter regulation by the class II transactivator and the thyroid Y box protein.
    Montani V; Taniguchi SI; Shong M; Suzuki K; Ohmori M; Giuliani C; Napolitano G; Saji M; Fiorentino B; Reimold AM; Ting JP; Kohn LD; Singer DS
    Endocrinology; 1998 Jan; 139(1):280-9. PubMed ID: 9421426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular analysis of HLA-DR gene expression induced by IFN-gamma in malignant melanoma cell lines.
    Lee JL; Kim YH; Lee JM; Kim JD; Kim SJ; Park JH
    Yonsei Med J; 1999 Feb; 40(1):30-9. PubMed ID: 10198604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of an interferon-gamma response region 5' of the human histocompatibility leukocyte antigen DR alpha chain gene which is active in human glioblastoma multiforme lines.
    Basta PV; Sherman PA; Ting JP
    J Immunol; 1987 Feb; 138(4):1275-80. PubMed ID: 3027177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation of the HLA-DR alpha gene is positively correlated with expression.
    Lee JS; O'Neill L
    Immunogenetics; 1987; 26(1-2):92-8. PubMed ID: 2440802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MHC class II deficiency syndrome: heterogeneity at the level of the response to 5-azadeoxycytidine.
    Lambert M; van Eggermond MC; Kraakman ME; Schuurman RK; van den Elsen PJ
    Res Immunol; 1990 Feb; 141(2):129-40. PubMed ID: 1697090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells.
    Rigaud G; De Lerma Barbaro A; Nicolis M; Cestari T; Ramarli D; Riviera AP; Accolla RS
    J Immunol; 1996 Jun; 156(11):4254-8. PubMed ID: 8666795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential susceptibility to modulation by recombinant immune interferon of HLA-DR and -DQ antigens synthesized by melanoma COLO 38 cells.
    Giacomini P; Aguzzi A; Ferrone S
    Hybridoma; 1986; 5(4):277-88. PubMed ID: 3100420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.